Summary

Location
at San Francisco, California and other locations
Dates
study started
study ends around

Description

Summary

The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients with PH.

Official Title

An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria

Keywords

Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease, Primary Hyperoxaluria Type 3 (PH3), Primary Hyperoxaluria, PH1, PH2, RNAi, GalNAc, LDHA, LDH, siRNA, PH3, Inborn Genetic Diseases, DCR-PHXC, Open Label

Eligibility

Locations

  • Clinical Research Site
    San Francisco California 94143 United States
  • Clinical Trial Site
    Rochester Minnesota 55905 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
ID
NCT04042402
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 75 study participants
Last Updated